These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36927689)

  • 21. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-302c enhances the chemosensitivity of human glioma cells to temozolomide by suppressing P-gp expression.
    Wu Y; Yao Y; Yun Y; Wang M; Zhu R
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31409725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.
    Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X
    Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
    Li XQ; Ouyang ZG; Zhang SH; Liu H; Shang Y; Li Y; Zhen YS
    J Neurooncol; 2014 Aug; 119(1):91-100. PubMed ID: 24842385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
    Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
    J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.
    Si J; Li W; Li X; Cao L; Chen Z; Jiang Z
    Cancer Sci; 2021 Sep; 112(9):3491-3506. PubMed ID: 34036683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
    Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study.
    Yu Y; Wang A; Wang S; Sun Y; Chu L; Zhou L; Yang X; Liu X; Sha C; Sun K; Xu L
    Mol Pharm; 2022 Apr; 19(4):1219-1229. PubMed ID: 35262365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
    Zhou L; Huang X; Zhang Y; Wang J; Li H; Huang H
    Brain Behav; 2022 May; 12(5):e2531. PubMed ID: 35380741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
    Liu T; Li A; Xu Y; Xin Y
    Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair.
    Sun Y; Liu X; Wu Z; Wang X; Zhang Y; Yan W; You Y
    J Mol Neurosci; 2023 May; 73(4-5):259-268. PubMed ID: 37014544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment.
    Wang R; Liang Q; Zhang X; Di Z; Wang X; Di L
    Colloids Surf B Biointerfaces; 2022 Jul; 215():112505. PubMed ID: 35487070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
    Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
    Yin H; Cui X
    Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
    [No Abstract]   [Full Text] [Related]  

  • 38. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.
    Wu S; Calero-Pérez P; Villamañan L; Arias-Ramos N; Pumarola M; Ortega-Martorell S; Julià-Sapé M; Arús C; Candiota AP
    NMR Biomed; 2020 Apr; 33(4):e4229. PubMed ID: 31926117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.